Targeted Therapy, Driven by Comprehensive Genomic Profiling and Molecular Tumour Board, Improves Outcomes In Pretreated Patients with Metastatic Cancer
Findings from the ROME study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
Trastuzumab Deruxtecan Prolongs PFS After Endocrine-Based Therapy in Patients with HR-positive, HER2-low or HER2-ultralow Metastatic Breast Cancer
Findings from the DESTINY-Breast06 study
Insights Into the Biology of Response and Resistance to MAPK Pathway Targeted Therapy in Patients with BRAFV600E-mutated mCRC
Findings from prespecified, exploratory biomarker analysis of BEACON CRC study
FDA Approves Neoadjuvant/Adjuvant Nivolumab for Resectable Non-Small Cell Lung Cancer
Evidence for efficacy is based on the results from the CHECKMATE-77T study
EMA Recommends Extension of Therapeutic Indications for Daratumumab
New indication concerns a combination with bortezomib, lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant
Pembrolizumab Plus Chemoradiotherapy Significantly Improves OS in Patients with Locally Advanced Cervical Cancer
Overall survival results from the second interim analysis of the ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
10-Year Data Underscore How ICI Therapy Has Helped to Change the Long-Term Prognosis for Patients with Advanced Melanoma
Final results from the CheckMate 067 study
Efficacy of Tivozanib Monotherapy in the Post-ICI Setting Among Patients with Advanced Renal Cell Cancer
Findings from the TiNivo-2 study
FDA Approves Osimertinib for Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Following Chemoradiation Therapy
Evidence for efficacy is based on the results from the LAURA study
EMA Recommends Additional Extensions of Indications for Pembrolizumab
New indications concern treatment of locally advanced cervical cancer in combination with chemoradiotherapy and first-line treatment of advanced or recurrent endometrial carcinoma in combination with chemotherapy
Benefit in OS with Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with Resectable, Early-Stage NSCLC
Findings from the second interim analysis of the KEYNOTE-671 study
Evidence for the Utility of ctDNA Monitoring for Recurrence After CRC Resection and Mortality Risk Stratification for Guiding Adjuvant Therapy
Findings from an updated analysis of the CIRCULATE-Japan GALAXY study